- Home
- DFIN vs ABSI Comparison
DFIN vs ABSI Comparison
Compare DFIN & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DFIN | ABSI |
|---|---|---|
| Founded | 1983 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 997.8M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DFIN | ABSI |
|---|---|---|
| Price | $48.16 | $8.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $61.50 | $6.96 |
| AVG Volume (30 Days) | 199.7K | ★ 2.7M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.64 |
| EPS | ★ 2.72 | N/A |
| Revenue | ★ $963,000,000.00 | $4,534,000.00 |
| Revenue This Year | $4.98 | $215.96 |
| Revenue Next Year | $3.87 | $319.10 |
| P/E Ratio | $17.76 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $36.11 | $2.24 |
| 52 Week High | $57.23 | $12.06 |
Technical Indicators
Market Signals| Indicator | DFIN | ABSI |
|---|---|---|
| Relative Strength Index (RSI) | 51.47 | 48.24 |
| Support Level | $45.09 | $8.55 |
| Resistance Level | $50.64 | $10.03 |
| Average True Range (ATR) | 1.43 | 0.57 |
| MACD | -0.14 | -0.06 |
| Stochastic Oscillator | 37.61 | 16.22 |
Price Performance
Historical ComparisonAbout DFIN Donnelley Financial Solutions Inc.
Donnelley Financial Solutions Inc is a risk and compliance software solutions and related services provider. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. It operates in four reportable segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management (its key revenue-generating segment), Investment Companies - Software Solutions, and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States (USA), Europe, Asia, Canada, and Others, of which the USA accounts for the vast majority of its total revenue.
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.